Corbus Pharmaceuticals Holdings Inc.

1.75-0.0300-1.69%Vol 410.49K1Y Perf -70.02%
Apr 23rd, 2021 10:31 DELAYED
BID1.75 ASK1.76
Open1.76 Previous Close1.78
Pre-Market1.79 After-Market-
 0.01 0.55%  - -
Target Price
2.30 
Analyst Rating
Strong Buy 1.00
Potential %
30.67 
Finscreener Ranking
★★★+     53.21
Insiders Trans % 3/6/12 mo.
-/-50/-50 
Value Ranking
     40.32
Insiders Value % 3/6/12 mo.
-/-96/-96 
Growth Ranking
★★+     50.91
Insiders Shares Cnt. % 3/6/12 mo.
-/-95/-95 
Income Ranking
 —    -
Market Cap218.81M 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
9.47 
Earnings Date
10th May 2021

Today's Price Range

1.721.79

52W Range

0.91009.78

5 Year PE Ratio Range

-10.80-8.70

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
3.49%
1 Month
-16.43%
3 Months
-15.64%
6 Months
76.24%
1 Year
-70.02%
3 Years
-73.23%
5 Years
-25.21%
10 Years
-

TickerPriceChg.Chg.%
CRBP1.75-0.0300-1.69
AAPL133.051.11000.84
GOOG2 280.7812.86000.57
MSFT258.231.06000.41
XOM55.820.55001.00
WFC43.620.92002.15
JNJ164.78-0.4000-0.24
FB297.681.16000.39
GE13.570.16001.19
JPM149.382.01001.36
Financial StrengthValueIndustryS&P 500US Markets
2.80
2.90
0.36
0.59
-305.30
Leverage Ratio 2.10
ProfitabilityValueIndustryS&P 500US Markets
-
-2 207.40
-2 178.90
-1 310.60
-
RevenueValueIndustryS&P 500US Markets
2.18M
0.02
47.76
58.55
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.22-0.1054.55
Q03 2020-0.41-0.43-4.88
Q02 2020-0.38-0.52-36.84
Q01 2020-0.43-0.430.00
Q04 2019-0.34-0.41-20.59
Q03 2019-0.36-0.3211.11
Q02 2019-0.220.03113.64
Q01 20190.02-0.43-2 250.00
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.150.00-
6/2021 QR-0.1318.75Positive
12/2021 FY-0.5231.58Positive
12/2022 FY-0.4752.53Positive
Next Report Date10th May 2021
Estimated EPS Next Report-0.15
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume410.49K
Shares Outstanding125.03M
Trades Count1.42K
Dollar Volume25.96M
Avg. Volume12.38M
Avg. Weekly Volume2.53M
Avg. Monthly Volume3.17M
Avg. Quarterly Volume12.75M

Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) stock closed at 1.78 per share at the end of the most recent trading day (a 1.71% change compared to the prior day closing price) with a volume of 2.41M shares and market capitalization of 218.81M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 141 people. Corbus Pharmaceuticals Holdings Inc. CEO is Yuval Cohen.

The one-year performance of Corbus Pharmaceuticals Holdings Inc. stock is -70.02%, while year-to-date (YTD) performance is 42.4%. CRBP stock has a five-year performance of -25.21%. Its 52-week range is between 0.91 and 9.78, which gives CRBP stock a 52-week price range ratio of 9.47%

Corbus Pharmaceuticals Holdings Inc. currently has a PE ratio of -1.20, a price-to-book (PB) ratio of 4.75, a price-to-sale (PS) ratio of 98.87, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -142.84%, a ROC of -276.81% and a ROE of -428.13%. The company’s profit margin is -%, its EBITDA margin is -2 178.90%, and its revenue ttm is $2.18 Million , which makes it $0.02 revenue per share.

Of the last four earnings reports from Corbus Pharmaceuticals Holdings Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.15 for the next earnings report. Corbus Pharmaceuticals Holdings Inc.’s next earnings report date is 10th May 2021.

The consensus rating of Wall Street analysts for Corbus Pharmaceuticals Holdings Inc. is Strong Buy (1), with a target price of $2.3, which is +30.67% compared to the current price. The earnings rating for Corbus Pharmaceuticals Holdings Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Corbus Pharmaceuticals Holdings Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Corbus Pharmaceuticals Holdings Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 28.21, ATR14 : 0.24, CCI20 : -42.25, Chaikin Money Flow : -0.02, MACD : -0.18, Money Flow Index : 28.71, ROC : -4.81, RSI : 45.08, STOCH (14,3) : 43.48, STOCH RSI : 1.00, UO : 45.35, Williams %R : -56.52), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Corbus Pharmaceuticals Holdings Inc. in the last 12-months were: Sean F. Moran (Option Excercise at a value of $182 228), Sean F. Moran (Sold 178 033 shares of value $276 807 ), Yuval Cohen (Buy at a value of $5 126)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
4 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

CEO: Yuval Cohen

Telephone: +1 617 963-0100

Address: 500 River Ridge Drive, Norwood 02062, MA, US

Number of employees: 141

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

67%33%

Bearish Bullish

52%48%

News

Stocktwits